
Tuesday, May 28, 2019 8:08:16 PM
Liked By
Spread the love. Be the first to like this post!
Recent HROW News
- Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation • Business Wire • 09/26/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2023 10:39:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:30:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:26:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:05:41 PM
- Harrow Announces Second Quarter 2023 Financial Results • Business Wire • 08/09/2023 08:01:00 PM
- Harrow Launches VIGAMOX® in the U.S. • Business Wire • 07/31/2023 11:00:00 AM
- Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 • Business Wire • 07/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/20/2023 11:46:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/20/2023 11:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/19/2023 09:19:37 PM
- Harrow Prices $60 Million Public Offering of Common Stock • Business Wire • 07/19/2023 11:00:00 AM
- Harrow erwirbt US-amerikanische und kanadische Vermarktungsrechte für VEVYE® (Cyclosporin-Augenlösung) 0,1 % von Novaliq • Business Wire • 07/19/2023 02:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/18/2023 09:03:23 PM
- Harrow Acquires Santen’s Branded Ophthalmic Portfolio • Business Wire • 07/18/2023 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 08:59:25 PM
- Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance • Business Wire • 07/18/2023 08:05:00 PM
- Harrow Announces Proposed Public Offering of Common Stock • Business Wire • 07/18/2023 08:04:00 PM
- Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq • Business Wire • 07/18/2023 08:01:00 PM
- Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 • Business Wire • 05/17/2023 12:00:00 PM
- Harrow Announces First Quarter 2023 Financial Results • Business Wire • 05/11/2023 08:01:00 PM
- Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting • Business Wire • 05/04/2023 12:00:00 PM
- Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. • Business Wire • 05/02/2023 11:00:00 AM
- Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 • Business Wire • 04/27/2023 12:00:00 PM
FEATURED SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split • Sep 27, 2023 9:49 AM
FEATURED 1606 Corp. Partners with Cool Blue To Launch ChatCBD, a New AI Customer Experience • Sep 26, 2023 8:37 AM
Branded Legacy Inc. Invests Heavily in Innovation and Growth with $540,000 Expansion • BLEG • Sep 26, 2023 10:37 AM
Avant Technologies Reshaping Future of Supercomputing and AI with Disruptive Private Cloud Infrastructure • AVAI • Sep 26, 2023 8:45 AM
Image Protect Announces Debt Forgiveness in Excess of $1,400,000 Clearing the Path for Pending New Business Development • IMTL • Sep 26, 2023 8:16 AM
CGrowth Capital Inc. Nears Key Milestone in Lithium Mining Expansion • CGRA • Sep 26, 2023 8:08 AM